Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Dengue Vaccine Formulation 17 · 1 trial · 1 indication
Number of solicited general symptoms within the 21-day follow-up after dengue dose 1 (total vaccinated cohort).
| Arm | Type | Description |
|---|---|---|
| Dengue and Japanese Encephalitis vaccine | EXPERIMENTAL | 1 mL subcutaneous injection Dengue Vaccine Formulation 17 on Day 0 and Day 60. 0.5 mL subcutaneous injection Licensed Japanese Encephalitis (JE) Vaccine on months 7 and 7.5. |
| Name | Type | Description |
|---|---|---|
| Dengue Vaccine Formulation 17 | BIOLOGICAL | Tetravalent live attenuated DEN vaccine candidate. Containing dengue serotypes 1,2, and 3 vaccines produced at the Salk Institute and dengue serotype 4 produced at the WRAIR Pilot Bioproduction Facility. Dosage 1 mL administered via injection at Day 0 and Day 60. |
| Licensed Japanese Encephalitis (JE) Vaccine | BIOLOGICAL | Produced by the Thailand GPO using a Beijing strain of JE in liquid form; dosed at 0.5 mL ot 7 and 7.5 months. |
Inclusion Criteria: * A male or female child six to nine years of age (greater than or equal to 6 years of age and less than 10 years of age) at the time of the first vaccination. * Free of obvious health problems as established by medical history and physical examination before entering into the s...
Dengue Vaccine Formulation 17 is an investigational vaccine being developed for the prevention of Dengue Fever. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The vaccine is intended for use in individuals at risk of dengue infection.
Dengue Vaccine Formulation 17 is being developed by GSK plc, a global biopharmaceutical company listed on the stock exchange under the ticker GSK. The company is conducting clinical trials to evaluate the safety and immunogenicity of this investigational dengue vaccine.
Dengue Vaccine Formulation 17 is in Phase 1 clinical development. It is an investigational vaccine and has not yet received regulatory approval. The Phase 1 trial has been completed, and the vaccine remains in early-stage clinical evaluation for the prevention of Dengue Fever.
Dengue Vaccine Formulation 17 has been studied in one completed Phase 1 clinical trial, identified as NCT00384670. This trial was a Phase I/II study of a tetravalent live attenuated dengue vaccine in flavivirus antibody naive children, conducted in Thailand with 7 participants.
Dengue Vaccine Formulation 17 is a tetravalent live attenuated dengue vaccine, meaning it contains weakened forms of all four dengue virus serotypes. It is designed to stimulate the immune system to produce protective antibodies against dengue virus infection, potentially reducing the risk of Dengue Fever.